Skip to main content

TRICCAR, Inc. (TCCR)

New York Stock Exchange Healthcare BiotechnologyView data quality →
38.8Poor

ValueMarkers Composite Index

Top 5%#42,592 of 44,707

DCF data not available

Piotroski
5/9
Neutral
Beneish
-
Altman
-104.51
Distress
DCF Value
-
N/A
ROIC
-166.2%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

TRICCAR, Inc. (TCCR) — VMCI valuation read

TRICCAR, Inc. sits at VMCI 39/100, with the Healthcare sector median at 50. That 11-point spread is the first thing to note on TCCR: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on TCCR are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on TCCR: TCCR trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 0.9x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

TCCR fell 1.8% over the trailing 7 days, with a -15.4% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TCCR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.